Work

Selective Induction of Estrogen Receptor-Dependent Stress Signaling as a Therapeutic Strategy in Resistant Breast Cancer

Year: 2026

Type: editorial

Abstract: Estrogen receptor alpha (ERα) is the defining therapeutic target in hormone receptor-positive breast cancer, yet acquired resistance remains a persistent barrier to durable clinical benefit. Patent application WO 2026/039467 A1 discloses small molecules that activate an anticipatory unfolded protein response (a-UPR) through ERα, converting receptor engagement into selective cytotoxic stress. This mechanism diverges fundamentally from classical antagonism or degradation and demonstrates preferential activity in ERα-positive tumor modelsoffering a conceptually distinct strategy for overcoming endocrine resistance.

Source: ACS Medicinal Chemistry Letters

DOI: 10.1021/acsmedchemlett.6c00171

Authors: Anna C. Renner, Robert B. Kargbo

Institution: North Dakota State University

Language: English

Topic: Estrogen and related hormone effects

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7154379453

Cites: 6

Cited by:

Related to: